Nicole Germino
Stock Analyst at Truist Securities
(2.04)
# 3,455
Out of 4,818 analysts
22
Total ratings
36.84%
Success rate
-2.96%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Nicole Germino
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CATX Perspective Therapeutics | Maintains: Buy | $21 → $10 | $2.34 | +327.35% | 2 | Apr 7, 2025 | |
| YMAB Y-mAbs Therapeutics | Maintains: Buy | $21 → $18 | $4.14 | +334.78% | 2 | Mar 5, 2025 | |
| INSM Insmed | Maintains: Buy | $105 → $108 | $70.87 | +52.39% | 8 | Feb 21, 2025 | |
| SGMO Sangamo Therapeutics | Maintains: Buy | $7 → $5 | $0.76 | +557.81% | 5 | Jan 23, 2025 | |
| ASMB Assembly Biosciences | Downgrades: Hold | $132 → $24 | $10.63 | +125.78% | 3 | Oct 24, 2022 | |
| FBRX Forte Biosciences | Downgrades: Hold | n/a | $6.02 | - | 2 | Sep 3, 2021 |
Perspective Therapeutics
Apr 7, 2025
Maintains: Buy
Price Target: $21 → $10
Current: $2.34
Upside: +327.35%
Y-mAbs Therapeutics
Mar 5, 2025
Maintains: Buy
Price Target: $21 → $18
Current: $4.14
Upside: +334.78%
Insmed
Feb 21, 2025
Maintains: Buy
Price Target: $105 → $108
Current: $70.87
Upside: +52.39%
Sangamo Therapeutics
Jan 23, 2025
Maintains: Buy
Price Target: $7 → $5
Current: $0.76
Upside: +557.81%
Assembly Biosciences
Oct 24, 2022
Downgrades: Hold
Price Target: $132 → $24
Current: $10.63
Upside: +125.78%
Forte Biosciences
Sep 3, 2021
Downgrades: Hold
Price Target: n/a
Current: $6.02
Upside: -